semaglutide weight loss what is it Shines as Therapy How Does Wegovy Work for

Access expert support and the latest treatment including Wegovy

Sobre el autor

It was not until February 2023 that once-weekly SC semaglutide 2.4 mg (Wegovy®) was approved for obesity treatment, and in the following month, tirzepatide (Mounjaro®) received approval for the treatment of T2D

No account required.

While the absolute risk increase was modest, our findings point to an important potential adverse effect that clinicians should consider, especially in patients with predisposing factors for GERD

GLP-1 agonists have demonstrated safety and efficacy in clinical trials for weight loss, but individual safety depends on medical history, dosing protocol, and ongoing provider oversight